肿瘤细胞治疗研究
英文原题：Therapeutic approaches to modulate the immune microenvironment in gliomas.
在过去十年中，包括免疫检查点抑制剂在内的免疫调节疗法已大幅改变某些癌症类型的结局。
包括免疫检查点抑制剂在内的免疫调节治疗，在过去十年中大幅改善了某些癌症的结局。胶质瘤从这些药物中获益有限，多数试验结果为阴性。胶质瘤免疫微环境的独特组成是疗效不足的原因之一。近年来，研究者为加深对胶质瘤免疫微环境的理解付出了大量努力，希望为新型治疗干预铺路。本综述讨论胶质瘤免疫微环境的若干主要组成部分，包括巨噬细胞、髓源性抑制细胞、中性粒细胞、小胶质细胞及淋巴细胞。随后全面概述目前处于临床开发阶段的新型免疫调节药物，包括溶瘤病毒、疫苗、CAR-T 和 CAR-NK 等细胞疗法，以及抗体和肽类药物。
Immunomodulatory therapies, including immune checkpoint inhibitors, have drastically changed outcomes for certain cancer types over the last decade. Gliomas are among the cancers that have seem limited benefit from these agents, with most trials yielding negative results. The unique composition of the glioma immune microenvironment is among the culprits for this lack of efficacy. In recent years, several efforts have been made to improve understanding of the glioma immune microenvironment, aiming to pave the way for novel therapeutic interventions. In this review, we discuss some of the main components of the glioma immune microenvironment, including macrophages, myeloid-derived suppressor cells, neutrophils and microglial cells, as well as lymphocytes. We then provide a comprehensive overview of novel immunomodulatory agents that are currently in clinical development, namely oncolytic viruses, vaccines, cell-based therapies such as CAR-T cells and CAR-NK cells as well as antibodies and peptides.
MEMBER ACCOUNT
登录成功会直接打开下一页。
